Telix Pharmaceuticals Limited (TLX) is in Healthcare, Biotechnology, based in Australia, listed on NasdaqGS. Market cap 3.73B USD. 52-week range 6.28 to 13.11 USD. Trailing P/E 110.1. Data as of 2026-10-09.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops ...